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Poster Session I S267Discussion: The above results suggest that inhibition of NFATc2
signaling in CD34+ HSC using CSA results in more rapid differen-
tiation towards the myelomonocytic and erythroid lineage (as seen
by flow cytometry) without affecting cell proliferation. These results
need to be further validated by RNAi mediated NFATc2 knock out
in HSC’s in vitro. These studies will lead to better understanding of
regulation of HSC differentiation and may have implications for
routine CSA administration in patients undergoing allogeneic
transplantation.
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EVALUATION OF TRANSPLANT CENTER UNRELATED DONOR SEARCH
STRATEGY PROFICIENCY
Malmberg, C.L., Davis, J., Beduhn, E., Buck, K., Chitphakdithai, P.,
Hermanson, J., Kempenich, J., Maus, T., Olson, K., Tram, K.,
Wood, J. National Marrow Donor Program, Minneapolis, MN
The National Marrow Donor Program (NMDP) evaluated the
proficiency ofU.S. transplant centers (TC) in selecting unrelated do-
nors (URD) for hematopoietic cell transplantation. The study iden-
tifies TC specific and individual search specific factors that influence
the likelihood of the best matched donors being selected for further
typing.We also evaluated changes in search proficiency since a com-
parable study in 2005.
Methods: Up to five random new patient searches of the Be
The Match Registry were evaluated for each TC from June –
September 2011; 25% accrued less than five. All searches were eval-
uated by HLA experts for three search proficiency characteristics:
patient HLA typing (loci/resolution), search strategy approach (se-
lect best potential HLA match), and number of donors selected for
further typing - each were given a score from 0-3. A total score
was calculated per search and stratified into high (perfect) and low
(not perfect) proficiency groups. Five factors were evaluated for cor-
relation to proficiency: use of NMDP search services - Search Strat-
egy Advice or Custom Search Support (CSS), presence of Certified
Hematopoietic Transplant Coordinator (CHTC) staff, URD pro-
curements (FY 2010), and difficult search (Yes/No).
Results: 566 patient searches from 130 TCs were included in the
current study; 76% rated in the high proficiency group and 24% in
the low. Univariate andmultivariate analysis concurred that searches
which received CSS, were performed at TCs with CHTC staff, or
were not difficult were more likely to have a high proficiency rating
(Table 1). Searches that received CSS were more than four times as
likely to have the highest proficiency rating. Similarly, searches at
TCs that had CHTC staff were about two times as likely to be high
proficiency while searches that were not difficult were about 1.5
times as likely. The majority of searches in the low proficiency group
did not select an adequate number of donors.
Conclusions: U.S. TCs have improved their search proficiency
from 52% in the high proficiency group in 2005 to 76% in 2011.
During this time, NMDP initiatives which may have influenced
TC proficiency include publications (NMDP matching guidelines),
a new search service (CSS), HapLogic predictions and donor list
sorting, and network education. The most frequent characteristic
of searches in the low proficiency group was selecting an inadequate
number of donors for extended typing which can delay a search.
Table 1. Logistic Regression Results for Search Proficiency
Rating
FavorableFactor N OR (95% CI) p-value characteristicProcurement Level 0.073 Not significantLow 81 1.00Medium 350 1.89 (0.84-4.25) 0.127(Continued )Table 1. (Continued)Factor N OR (95% CI) p-valueFavorable
characteristicHigh 135 1.05 (0.45-2.46) 0.907CSS sent to TC
before formalCSS sent to TC
before formalYes 71 4.13 (1.39-12.28) 0.011No 495 1.00SSA sent to TC
before formalNot significantYes 32 1.13 (0.47-2.74) 0.781No 534 1.00At least 1 CHTC
on staffHad at least
1 CHTC staffYes 239 2.07 (1.22-3.50) 0.007No 327 1.00Difficult search Not difficultYes 226 0.63 (0.42-0.93) 0.020No 340 1.00OR indicates odds ratio; CI indicates confidence interval173
EXPANSION OF T-CELLS FROM THE CORD BLOOD GRAFT AS A PREDIC-
TIVE TOOL FOR COMPLICATIONS AND OUTCOME OF CORD BLOOD
TRANSPLANTATION
Gertow, J.1, Berglund, S.1, Okas, M.1, K€arre, K.2, Remberger, M.1,
Mattsson, J.1, Uhlin, M.1 1Karolinska University Hospital Huddinge,
Stockholm, Sweden; 2Karolinska Institutet, Stockholm, Sweden
We have previously successfully expanded functional T-cells in
vitro from cord blood grafts used for clinical transplantation,
with the aim of creating donor lymphocyte infusions to treat e.g.
malignant relapse. Here we show that the T cell expansion in ad-
dition might work as a prognostic tool for in vivo complications af-
ter transplantation. We used multi-color flow cytometry to
correlate in vitro phenotypical data from 33 expansions to the clin-
ical outcome post-transplantation. Higher levels of CD69+ acti-
vated T-cells in the expansion were associated with prolonged
survival of the patient. In addition, we found a correlation between
T-cell expansions containing relatively high levels of effector mem-
ory T-cells and transplant-related complications. Our data suggest
that expansions of cord blood T-cells from the graft might not only
be used as donor lymphocyte infusions, but also as in vitro indica-
tors that could give essential information on how to manage cord
blood transplanted patients.174
EFFECTIVENESS OF UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION: RESULTS OF A DONOR VS. NO DONOR
ANALYSIS
Pidala, J., Kim, J., Schell, M., Hillgruber, R., Nye, V., Ayala, E.,
Alsina, M., Betts, B., Bookout, R., Fernandez, H.F., Field, T.,
Locke, F.L., Nishihori, T., Ochoa, J.L., Perez, L., Perkins, J.,
Shapiro, J., Tate, C., Tomblyn, M., Anasetti, C. Moffitt Cancer Center,
Tampa, FL
In a consecutive series of unrelated donor searches conducted
fromMarch, 2006 through December, 2009 at Moffitt Cancer Cen-
ter, we studied the following: (1) likelihood of finding a suitable (7-
8/8) high-resolution matched unrelated donor; (2) factors associated
with reaching transplant (HCT) among those with a donor; and (3)
the effect of unrelated donor vs. no donor status on survival by in-
tention to treat (ITT) analysis. Those with a fully HLA-A, -B, -C,
and –DRB1 (8/8) matched or single locus (7/8) mismatched unre-
lated donor were defined as donor (n 5 448), while those without
were no donor (n 5 83). Median time from search initiation to do-
nor identification was 21 days; 95% of these values were within 59
S268 Poster Session Idays. While race/ethnicity (p\0.0001) and disease (p 5 0.01) were
associated with finding a donor, other variables (age, gender,
CIBMTR risk, CMV, KPS, socio-economic status) were not.
Among those with a donor, logistic regression modeling identified
increasing age (p 5 0.02), non-Caucasian race/ethnicity (p 5
0.002), and high CIBMTR risk (p 5 0.007) as associated with de-
creased odds for reaching HCT. Among 448 patients in the donor
group, 239 underwent HCT. Of those in the no donor group, a total
of 14 underwent double umbilical cord blood transplant (dUCBT).
In the primary ITT analysis, we studied outcome according to
donor vs. no donor status from time of search initiation using
a time-dependent Cox model. Compared to no donor, donor status
had reduced hazard for mortality (HR of 0.85, 95% CI 0.63 -1.2,
p 5 0.3). Accounting for interaction, those with KPS 90-100 and
donor had significantly reduced hazard (HR 0.59, 95% CI 0.38 -
0.90, p 5 0.02) compared to no donor. Secondary analyses exam-
ined outcome by treatment received: Those who received the
intended HCT in the donor group had significantly reduced hazard
(HR 0.64, 95%CI 0.46 – 0.89, p5 0.009) compared to no donor. In
a separate analysis, donor, dUCBT, and no donor/no UCBT were
treated as time-varying covariates, demonstrating significantly re-
duced hazard for donor vs. no donor (HR 0.57, 95% CI 0.43-
0.76, p 5 0.0001). No significant effect of matching (7/8 vs. 8/8)
was detected in any analyses. In total, these data provide new insight
into factors associated with unrelated donor identification according
to high-resolution typing methods, identify factors relevant to
reaching HCT among those with a suitable donor, and speak to
the efficacy of unrelated donor HCT.175
UNRELATED CORD BLOOD TRANSPLANTATION (CBT) OF 101
HEMOGLOBINOPATHY (HGB) PATIENTS
Chow, R.Y.1, Jaing, T.-H.2, Chan, L.L.3, Tan, P.4, Lin, H.-P.5,
Graham, M.6, Rosenthal, J.7, Karanes, C.7, Nademanee, A.7,
Wang, B.C.8, Yen, L.8, Chow, M.R.8, Dang, T.8, Kurtzberg, J.9,
Petz, L.D.1 1StemCyte, Inc., Covina, CA; 2Chang Gung Children’s Hos-
pital, Linkou, Taiwan; 3University of Malaya, Kuala Lumpar, Malaysia;
4Mount Elizabeth Hospital, Singapore, Singapore; 5Subang Jaya Medical
Center, Kuala Lumpar, Singapore; 6Banner Thunderbird Medical Cen-
ter, Glendale, AZ; 7City of Hope National Medical Center, Duarte, CA;
8B.C.W. Statistical Consultants, Los Angeles, CA; 9Duke University
Medical Center, Durham, NC
Unrelated cord blood transplantation (CBT) is not widely used
to treat hemoglobinopathies (HGB) despite being the fastest grow-
ing stem cell source for unrelated hematopoietic cell transplanta-
tion (HCT). Published series show unfavorable disease-free
survival (Ruggeri et al. BBMT 2011) or were single institution
efforts (Jaing et al. BMT 2011). We analyzed the clinical outcome
for 101 HGB patients following CBT. The combination approach
to optimize nucleated cell (NC) dose of choosing CB products
manufactured by plasma depletion/reduction to maximize NC re-
covery, double grafts (whenever single CB had insufficient NC
dose), and post-thaw direct infusion were used by the 5 Asian
transplant centers (TCs) in this series that performed most of the
CBT. A CIBMTR on site-audited analysis was performed on 91
thalassemia and 10 sickle cell disease (SCD) patients transplanted
between 1999 and 2011 at 25 TCs in 6 countries using 114 CB
products processed by plasma depletion/reduction (88%) and 15
CB units processed by red cell reduction. 84% of the CB were in-
fused directly without post-thaw wash/reconstitution and 19% of
the transplants employed double CB grafts. Most TCs reported us-
age of no-TBI preparative regimens or ones that included Bu/Cy/
ATG. Graft failure rate at some TCs declined after switching from
oral busulfan to IV formulations, and 7 patients received a second
CBT. 24% of the transplants (24 patients/25 CB) were performed
at 18 U.S. TCs with the remainder (77 patients/104 CB) at 7 inter-
national TCs. 75% of the patients were Asian. Median follow-up
time was 711 days (range 2-2,877 days). Transplant characteristics:
median age 5.6 years (range 0.3-20); median patient weight 18.8 kg
(range 4-80); male 45%; HLA matches (intermediate resolution
HLA-A and -B and high resolution HLA-DRB1) of the CB used
in these patients: 6/6-23; 5/6-45; 4/6-54; 3/6-3; median pre-freezeTNC dose 9.4 x107/kg; median pre-freeze CD34+ dose 3.2 x105/
kg. The median times to myeloid and platelet engraftment were
17 days and 47 days, respectively. Of the 101 patients, 21 expired
before 180 days (20.8%); 26 prior to 1 year (25.7%) and 27 total
deaths (26.7%). To our knowledge, the current multi-center study
with 101 patients is the largest unrelated CBT series for HGB or
thalassemia. The data appear to support the notion that in the set-
ting of optimal cell dose, favorable overall and disease-free survival
may be achieved for unrelated CBT of HGB/thalassemia.
Table. Summary of Patient, CB and Transplant Characteris-
tics
Thalassemia ThalassemiaPatient
CharacteristicsAll Patients
(n 5 101)PDR CB
(n 5 79)RCR CB
(n 5 12)SCD PDR
CB (n 5 9) CSCD RCR
B (n 5 1)Age yo,
Median (Range)
5.6 (0.3-20) 5.3 (0.3-20) 4.0 (0.8-12) 12.4 (4-20) NAWeight Kg, Median
(Range)
18.8 (4-80) 18.5 (8-45) 15.1 (4-36) 34.0 (17-80) NAMale Sex % 46 43 58 44 NAAsian/Caucasian/
AFA/NA %
75/9/8/9 71/4/0/4 4/5/0/3 0/0/8/1 0/0/0/1CB Graft
Characteristics
A
(ll CB
n 5 129)
T
Phalassemia
DR CB
(n 5 105)
T
R
(halassemia
CR CB
n 5 13)
S
CCD PDR
B (n 5 9) CSCD RCR
B (n 5 2)HLA Match
NA,3/6,4/6,
5/6,6/6
4,3,54,45,23 1,3,42,38,21 1,0,8,3,1 0,0,4,4,1 2,0,0,0,0Pre Freeze
TNC dose,
Median (Range)
9.4 (2.3-23.7) 9.8 (2.5-23.7) 8.7 (2.3-18.6) 4.4 (2.6-10) NAPre Freeze CD34+
dose, Median
(Range)
3.2 (0.4-13.5) 3.6 (0.4-10.3) 1.5 (0.4-13.5) 1.8 (0.8-3.1) NA% CB bedside thaw 84 89 77 56 0% Double CBT 19 20 8 0 100PDR 5 Plasma Depleted/Reduced; RCR 5 Red Cell Reduced; CB 5
Cord Blood; yo5 years old; Asian5 Asian/Asian Pacific Islander/Indian;
Caucasian 5 Causian/Middle Eastern; AFA 5 African American; NA 5
Not Availlable; TNC 5 Total Nucleated Cells in 107; CD34+ cells in
10^5; beside thaw 5 direct infusion without post-thaw wash or
reconstitution176
HLA-DPA1 MISMATCH IS ASSOCIATED WITH DECREASED OVERALL
SURVIVAL FOLLOWING UNRELATED DONOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Olsson, R.1,2, Remberger, M.1,2, Ringden, O.1,2, Schaffer, M.1
1Karolinska Institutet, Stockholm, Sweden; 2Karolinska University
Hospital, Stockholm, Sweden
Aim: To investigate the impact of HLA-DPA1 and -DPB1 mis-
match on clinical outcomes in a modern era of unrelated hematopoi-
etic stem cell transplantation (HSCT).
Methods: Retrospectively, 380 consecutive patients (median age
39, range 0.5-67 years) who underwent HSCT using HLA -A,
-B, and -DRB1 allele level-matched unrelated donors at our centre
during 1995-2010, were included in the study. Most patients un-
derwent HSCT in the treatment for hematological malignancies
(81%), whereas 7% and 12% of all patients were transplanted in
the treatment for non-hematological malignancies and non-malig-
nant disorders, respectively. HLA typing using PCR-SSP (Olerup-
SSP) or PCR-SSO on a Luminex platform (One Lambda) was
performed and revealed 55 HLA-DP (A1 and B1) matched and
325 mismatched donor pairs. HLA-DPA1 and HLA-DPB1 mis-
match was noted in 35% and 85% of all recipient donor pairs, re-
spectively.
